In the 1970s, we were the first company in our field to standardise the production of allergen extracts for use in allergy immunotherapy.

In the 1990s, we were the first company to launch sublingual allergy immunotherapy (SLIT) drops for allergy treatment - a decisive step towards making allergy immunotherapy more convenient for patients.

Groundbreaking asthma research
And in the 2000s, we developed the world’s first sublingual allergy immunotherapy tablet (SLIT-tablet), against grass pollen allergy.

Later, came SLIT-tablets against ragweed and house dust mite allergies – ALK's house dust mite SLIT-tablet being the first with an indication to treat both allergic rhinitis and allergic asthma.

Today, focus remains on completing a SLIT-tablet portfolio covering the most common global allergies and further documenting their benefits in the treatment of allergic asthma and asthma prevention.

We will also explore new technologies for the next generation of allergy immunotherapy.